医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Samsung Bioepis Receives Regulatory Approval for Europe’s First Trastuzumab Biosimilar, ONTRUZANT®

2017年11月20日 AM07:21
このエントリーをはてなブックマークに追加


 

INCHEON, Korea

Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) marketing authorization of ONTRUZANT®, a biosimilar referencing Herceptin® (trastuzumab), for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer. ONTRUZANT® is the first trastuzumab biosimilar to receive regulatory approval in Europe.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171119005066/en/

Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire)

Christopher Hansung Ko, President & CEO of Samsung Bioepis. (Photo: Business Wire)

The EC approval of ONTRUZANT® applies to all 28 European Union (EU) member states and the European Economic Area (EEA) member states of Norway, Iceland and Liechtenstein. ONTRUZANT® will be commercialized by MSD, which is known as Merck in the United States and Canada.

“Breast cancer remains the most common form of cancer affecting women. We hope ONTRUZANT will play an important role expanding patient access to trastuzumab across the region,” said Christopher Hansung Ko, President & CEO of Samsung Bioepis. “Through relentless process innovation and an uncompromising commitment to quality, we remain dedicated to advancing one of the industry’s strongest biosimilar pipelines, so that more cancer patients and healthcare systems across Europe will benefit from biosimilars.”

ONTRUZANT® is the fourth biosimilar developed by Samsung Bioepis to receive EC marketing authorization. Samsung Bioepis has also received marketing authorizations for Benepali® (etanercept), Flixabi® (infliximab) and Imraldi® (adalimumab).

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six first-wave candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

i Herceptin® is a registered trademark of Genentech Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171119005066/en/

CONTACT

MEDIA CONTACT:
Samsung Bioepis Co., Ltd.
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Humanigen Announces Closing of Public Offering of Common Stock
  • Masimo O3®を使用してCOVID-19患者の脳酸素化に及ぼす換気補助療法の影響を追究した研究
  • CoVIg-19プラズマ・アライアンス、COVID-19治療薬候補の高度免疫グロブリン製剤を評価するためにNIHが実施した臨床試験のトップライン結果を発表
  • CoVIg-19血浆联盟公布NIH发起的在研药物COVID-19超免疫球蛋白临床试验的顶线结果
  • DESTINY-CRC02 Phase 2 Trial of ENHERTU® Initiated in Patients with HER2 Overexpressing Advanced Colorectal Cancer